Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carbamates
Cetuximab
/ adverse effects
Colonic Neoplasms
/ drug therapy
Colorectal Neoplasms
/ drug therapy
Humans
Irinotecan
/ adverse effects
Mutation
Proto-Oncogene Proteins B-raf
/ genetics
Rectal Neoplasms
/ drug therapy
Sulfonamides
Technology Assessment, Biomedical
BRAF(V600E)-mutation
Irinotecan
Overall survival
Progression-free survival
Time-to-event
Journal
Clinical colorectal cancer
ISSN: 1938-0674
Titre abrégé: Clin Colorectal Cancer
Pays: United States
ID NLM: 101120693
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
13
03
2022
revised:
20
04
2022
accepted:
21
04
2022
pubmed:
3
6
2022
medline:
9
9
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
Purpose of this analysis was to report data of the BEACON CRC trial used in the German Health Technology Assessment (HTA) and previously unpublished data focusing on the dual blockade (encorafenib + cetuximab) and appropriate comparative therapy (ACT/control: cetuximab + irinotecan-based chemotherapy) of patients with BRAF Analyses included overall survival (OS) and time-to-event analyses of morbidity and safety. A total of 220 patients received encorafenib + cetuximab and 221 patients ACT/control. Median OS was 9.3 (encorafenib + cetuximab) versus 5.9 months (ACT/control) (stratified hazard ratio (HR In the HTA, the German G-BA granted a "hint for a considerable additional benefit" of encorafenib + cetuximab compared to the ACT in BRAF
Sections du résumé
BACKGROUND
Purpose of this analysis was to report data of the BEACON CRC trial used in the German Health Technology Assessment (HTA) and previously unpublished data focusing on the dual blockade (encorafenib + cetuximab) and appropriate comparative therapy (ACT/control: cetuximab + irinotecan-based chemotherapy) of patients with BRAF
MATERIALS AND METHODS
Analyses included overall survival (OS) and time-to-event analyses of morbidity and safety.
RESULTS
A total of 220 patients received encorafenib + cetuximab and 221 patients ACT/control. Median OS was 9.3 (encorafenib + cetuximab) versus 5.9 months (ACT/control) (stratified hazard ratio (HR
CONCLUSION
In the HTA, the German G-BA granted a "hint for a considerable additional benefit" of encorafenib + cetuximab compared to the ACT in BRAF
Identifiants
pubmed: 35654691
pii: S1533-0028(22)00041-X
doi: 10.1016/j.clcc.2022.04.002
pii:
doi:
Substances chimiques
Carbamates
0
Sulfonamides
0
Irinotecan
7673326042
encorafenib
8L7891MRB6
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Cetuximab
PQX0D8J21J
Banques de données
ClinicalTrials.gov
['NCT02928224']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
244-251Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.